Stromal cell

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Retrieved on: 
Wednesday, February 14, 2024
Janus, Poster, AAAAI, Jefferies Group, KIT, Prospectus, APEX, Part, Sale, PEAK, Webcast, Patient, Clinical trial, United, Stromal cell, American Academy, Research, Security (finance)

WALTHAM, Mass. and BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) --  Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $225 million to the Company, before deducting placement agent fees and offering expenses.

Key Points: 
  • ET on February 23 to review the SUMMIT Part 1b data with bezuclastinib at AAAAI annual meeting
    WALTHAM, Mass.
  • J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. acted as placement agents.
  • Cogent anticipates the gross proceeds from the private placement to be approximately $225 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about February 16, 2024, subject to customary closing conditions.

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Retrieved on: 
Monday, December 11, 2023
University of Alabama, Patient, Associate, Deficit spending, Division, BID, Efficacy, Part Two, Novel, Poster, APEX, American Society of Hematology, Liver injury, PPR, KIT, Society, Stromal cell, TKI, Clinical trial, Mast cell leukemia, ASH, University, VAF, Part, Biomarker, Webcast, Safety, ASM, PEAK, GIST, MCL, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive data from Part 1 of the Company’s ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the 65th American Society of Hematology (ASH 2023) Annual Meeting & Exposition taking place December 9-12, 2023 in San Diego, CA.

Key Points: 
  • “Advanced systemic mastocytosis is a serious and life-threatening disease,” said Pankit Vachhani, M.D., Associate Professor of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham.
  • Patients were enrolled with the following sub-types: seven patients with aggressive systemic mastocytosis (ASM), 23 patients with systemic mastocytosis with associated hematologic neoplasm (SM-AHN), and two patients with mast cell leukemia (MCL).
  • In addition, Cogent plans to present data from the completed SUMMIT Part 1 trial (1a and 1b) in the first quarter of 2024.
  • ET (5:00 a.m. PT) to discuss today’s APEX data and the SUMMIT data in NonAdvSM released on December 9.

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
Saturday, December 9, 2023
Patient, Cogent, OLE, MAS, Deficit spending, ISM, GIST, Fourth grade, Poster, Bleeding, American Society of Hematology, APEX, Disease, KIT, MD Anderson Cancer Center, Society, Stromal cell, SSM, PD, ASH, Mutation, VAF, Hyperkinesia, Part, PGIC, Webcast, Safety, University, PEAK, Dermatology, Pharmaceutical industry

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points: 
  • Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
  • Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
  • In patients with completed questionnaires:
    By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
  • Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board

Retrieved on: 
Tuesday, December 5, 2023
Fibromatosis, Surgical oncology, Radiology, STS, AG, Treatment, ESSO, Drug development, Research, Editor-in-chief, Thermosome, CMO, Stromal cell, Bristol Myers Squibb, SSO, Therapy, ISG, BioNTech, Society, Sarcoma, Oncology, Hematology, Board certification, Senior, Pharmaceutical industry

Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.

Key Points: 
  • Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.
  • Prior to that, he was Senior Director Clinical Development Oncology at BioNTech SE and Chief Development Officer at 4SC AG.
  • Earlier in his career, Frank Hermann worked in medical affairs and clinical development at Bristol-Myers Squibb, most recently as Associate Medical Director Immuno-Oncology.
  • “We are very pleased that Frank is joining Thermosome as Chief Medical Officer,” said Dr. Pascal Schweizer, co-founder, and CEO/CFO of Thermosome.

IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, TKI, Patient, KIT, PRS, MTD, MPH, Physician, BID, Exon, Poster, Strategist, UZ Leuven, Annual general meeting, GIST, RECIST, Stromal cell, Therapeutic index, Pharmaceutical industry, MD

“Importantly, these preliminary data will help guide our discussions with physicians regarding development strategies for IDRX-42 in patients with GIST in early lines of therapy to prevent the emergence of genomically-driven resistance mutations.

Key Points: 
  • “Importantly, these preliminary data will help guide our discussions with physicians regarding development strategies for IDRX-42 in patients with GIST in early lines of therapy to prevent the emergence of genomically-driven resistance mutations.
  • Median duration on treatment was 16 weeks and continuing, with 70% (23/33) of patients remaining on treatment at time of data cutoff.
  • 4/28 patients are on study for
  • Title: Phase 1 Study of IDRX-42 in Patients with Advanced Gastrointestinal Stromal Tumors Resistant to Prior Systemic Therapy: Early Results
    Session: CTOS Poster Reception 5:30-6:30 p.m. GMT, Thursday, November 2nd

Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology Study, Drug Insights, Price Reimbursement, and Regulatory Consulting Services | Disease Landscape Insights

Retrieved on: 
Monday, October 9, 2023
Carcinoid, CT, Diverticulitis, Smoking, Manga: The Complete Guide, Gist, Anemia, Human, Epidemiology, Weight loss, Rectum, Lymphoma, Sarcoma, Breast cancer, Market intelligence, Radiation, CRC, Disease, Colonoscopy, Cancer, Myth, EMA, FDA, Weakness, Environment, Signs and symptoms, Fatigue, Elijah Cummings Lower Drug Costs Now Act, Colorectal cancer, HPV, Colon, Stromal cell, Scrub typhus, Compensation, Blood, DLI, Patient, Pharmaceutical industry, Medical imaging, Dietary supplement, Vaccine, Pneumonia

The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.

Key Points: 
  • The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.
  • Apart from that ct scan colon cancer and ct scan for bowel cancer, may also be suggested for the detection of colorectal malignant neoplasm.
  • It has been assisting them with regulatory consulting, pharma consulting services, post launch strategies, product pipeline assessment, and treatment gaps identification.
  • Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Redefining Colorectal Cancer (CRC) Landscape Report with DLI's Epidemiology Study, Drug Insights, Price Reimbursement, and Regulatory Consulting Services | Disease Landscape Insights

Retrieved on: 
Monday, October 9, 2023
Carcinoid, CT, Diverticulitis, Smoking, Manga: The Complete Guide, Gist, Anemia, Human, Epidemiology, Weight loss, Rectum, Lymphoma, Sarcoma, Breast cancer, Market intelligence, Radiation, CRC, Disease, Colonoscopy, Cancer, Myth, EMA, FDA, Weakness, Environment, Signs and symptoms, Fatigue, Elijah Cummings Lower Drug Costs Now Act, Colorectal cancer, HPV, Colon, Stromal cell, Scrub typhus, Compensation, Blood, DLI, Patient, Pharmaceutical industry, Medical imaging, Dietary supplement, Vaccine, Pneumonia

The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.

Key Points: 
  • The diagnostic landscape of this disease is diverse wherein colonoscopy recommendations are given by doctors due to its accuracy.
  • Apart from that ct scan colon cancer and ct scan for bowel cancer, may also be suggested for the detection of colorectal malignant neoplasm.
  • It has been assisting them with regulatory consulting, pharma consulting services, post launch strategies, product pipeline assessment, and treatment gaps identification.
  • Find out more about Tonsillitis symptoms, consulting services, drug costs, FDA-approved medications, disease landscape, regulatory insights, epidemiology, and price reimbursement.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Morgan Stanley, GIST, Cogent, AACR, D, HER2, Sunitinib, DCR, G&A, PEAK, Stromal cell, ASCO, Patient, Morgan, Growth, Research, American Association for Cancer Research, APEX, FGFR2, Conference, ORR, Pharmaceutical industry, Cryptocurrency

WALTHAM, Mass. and BOULDER, Colo., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • and BOULDER, Colo., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2023.
  • R&D Expenses: Research and development expenses were $38.9 million for the second quarter of 2023 as compared to $29.5 million for the second quarter of 2022.
  • R&D expenses include non-cash stock compensation expense of $3.6 million for the second quarter of 2023 compared to $2.1 million for the second quarter of 2022.
  • G&A expenses include non-cash stock compensation expense of $3.6 million for the second quarter of 2023 compared to $2.4 million for the second quarter of 2022.